In the News

In the News
February 1, 2018

Medidata and Syapse tackling precision medicine challenges in new partnership

Medidata and Syapse have teamed up to develop a new suite of solutions, which will aim address precision medicine challenges and accelerate clinical research in oncology for trial sponsors.

In the News
January 29, 2018

What Apple’s Health Records update means for the clinical trials industry

Apple has updated its Health app to give users access to their medical records-a new feature that could fundamentally change the way research is conducted.

In the News
January 15, 2018

The doctor can see you now... from miles away

The modern pharmaceutical age has granted doctors a panoply of drugs to help with a variety of conditions, but how to ensure the patient takes them?

In the News
January 5, 2018

What Does 2018 Hold For Biopharma?

From ongoing progress in IO to revolutions in AI, and from pricing headaches to new therapies for a migraine: Scrip has gleaned from experts and industry executives their expectations and predictions for 2018's hot topics, featuring Medidata.

In the News
January 5, 2018

Clinical Trial Technologies for Precision Medicine: The Current State of the Art

Precision medicine is positioned to revolutionize the healthcare landscape, and the utilization of advanced clinical development technologies is key to supporting precision medicine trials. 

In the News
December 21, 2017

View from the Top, 2018 Chief Marketers Interview

Twenty CMOs sound off on the trends, challenges and opportunities B2C and B2B marketers face in 2018; featuring Medidata's CMO Simon Mouyal.

In the News
December 17, 2017

Innovators 2017: Products

PM360’s Innovations Issue was established six years ago to serve as a comprehensive guide of the year’s most innovative Companies, Products, and Services.

In the News
December 1, 2017

In-Depth: The rise of the digital clinical trial

The number of clinical trials that currently rely on antiquated, paper-based data collection is “pitiful”, considering what’s possible.